PuraPharm Corp. Ltd. (HK:1498)
:1498
Want to see HK:1498 full AI Analyst Report?
Top Page
PuraPharm Corp. Ltd.
(1498)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.31
▼(-10.86% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance—multi-year net losses, contracting revenue, and high leverage—despite strong gross margins and positive (but volatile) free cash flow. Technicals are only modestly supportive with short-term improvement but a longer-term downtrend. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
High Gross Margin
Sustained ~53% gross margin indicates meaningful product-level pricing power or low COGS in its TCM manufacturing business. This durable margin buffer supports absorption of SG&A and R&D, enabling longer-term reinvestment and resilience amid top-line pressure.
Negative Factors
Multi-year Net Losses
Persistent operating and net losses over several years erode retained earnings and capital base, constrain reinvestment, and hinder ability to build sustainable profitability. Continued below-line losses limit strategic flexibility and increase reliance on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
Sustained ~53% gross margin indicates meaningful product-level pricing power or low COGS in its TCM manufacturing business. This durable margin buffer supports absorption of SG&A and R&D, enabling longer-term reinvestment and resilience amid top-line pressure.
Read all positive factors
PuraPharm Corp. Ltd. (1498) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$155.13M
Dividend YieldN/A
Average Volume (3M)128.80K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth-12.03%
EPS Growth6.24%
CountryHK
Employees479
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.09
Shares Outstanding535,897,640
10 Day Avg. Volume96,100
30 Day Avg. Volume128,800
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.14
Price to Sales (P/S)0.44
P/FCF Ratio5.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PuraPharm Corp. Ltd. Business Overview & Revenue Model
Company Description
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates thr...
How the Company Makes Money
Revenue is generated primarily through sales of the company’s pharmaceutical and healthcare products. This typically includes (i) product sales to distributors, pharmacies, hospitals/clinics, and other healthcare channels, and (ii) direct sales wh...
PuraPharm Corp. Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
45
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 336.11M | 382.09M | 406.86M | 448.07M | 659.59M |
| Gross Profit | 180.16M | 205.14M | 216.63M | 260.59M | 421.85M |
| EBITDA | 6.23M | 17.35M | -26.31M | -46.34M | -40.03M |
| Net Income | -35.22M | -35.44M | -106.08M | -120.21M | -121.88M |
Balance Sheet | |||||
| Total Assets | 693.76M | 715.73M | 843.96M | 1.02B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 21.18M | 12.79M | 47.22M | 91.36M | 85.05M |
| Total Debt | 351.14M | 363.76M | 424.77M | 503.16M | 531.96M |
| Total Liabilities | 560.59M | 604.53M | 690.73M | 757.18M | 803.13M |
| Stockholders Equity | 130.48M | 111.20M | 153.24M | 258.29M | 401.56M |
Cash Flow | |||||
| Free Cash Flow | 25.69M | 89.18M | 57.95M | 42.29M | -45.89M |
| Operating Cash Flow | 28.52M | 103.98M | 79.61M | 65.85M | -39.33M |
| Investing Cash Flow | 24.12M | -11.71M | -18.20M | -25.45M | 6.00M |
| Financing Cash Flow | -46.34M | -86.43M | -122.39M | -12.94M | -13.87M |
PuraPharm Corp. Ltd. Technical Analysis
Negative
0.35
Price Trends
0.31
Negative
0.33
Negative
0.38
Negative
Market Momentum
<0.01
Positive
45.55
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1498, the sentiment is Negative. The current price of 0.35 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.31, and below the 200-day MA of 0.38, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.55 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1498.
PuraPharm Corp. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | HK$769.75M | 3.58 | 12.80% | 7.52% | -9.66% | 16.17% | |
68 Neutral | HK$2.54B | 3.07 | 19.22% | 15.97% | -20.14% | -20.91% | |
60 Neutral | HK$659.50M | 9.05 | 5.66% | 2.92% | 2.57% | -1.27% | |
54 Neutral | HK$203.00M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$367.75M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
45 Neutral | HK$155.13M | -3.07 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.24
-44.44%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.07
0.02
40.00%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.02
-5.71%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.14
-0.23
-16.79%
HK:0239
Pak Fah Yeow International Limited
2.48
0.23
10.22%
HK:6896
Golden Throat Holdings Group Co Ltd
3.40
-1.38
-28.87%
PuraPharm Corp. Ltd. Corporate Events
PuraPharm moves to modernise Articles of Association with electronic meeting and voting powers
Apr 30, 2026
PuraPharm Corporation Limited plans to amend its Articles of Association to align with the latest legal and regulatory requirements of the Hong Kong Stock Exchange, including changes to Appendix A1 of the Listing Rules effective 1 July 2025. The a...
PuraPharm Sets 2026 AGM to Confirm Board, Auditor and Share Buy-Back Mandate
Apr 30, 2026
PuraPharm Corporation Limited has called its annual general meeting for 27 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025. The meeting will also vot...
PuraPharm bolsters governance with new independent directors
Apr 27, 2026
PuraPharm Corporation Limited has strengthened its corporate governance structure with the appointment of Mr. Lee Stephen and Prof. Ng Wang Wai Charles as independent non-executive directors, effective 27 April 2026. Both will also serve on the au...
PuraPharm Updates Board Composition and Committee Roles
Apr 27, 2026
PuraPharm Corporation Limited has released an updated list of its board of directors and clarified their respective roles and functions across key governance committees. The company detailed the composition of executive, non-executive and independ...
PuraPharm Revenue Drops but Annual Loss Holds Steady in 2025
Mar 25, 2026
PuraPharm Corporation Limited reported a 12% year-on-year decline in 2025 revenue to HK$336.1 million, as sales of Hong Kong concentrated Chinese medicine granules and Nong’s-branded clinics fell and China concentrated granule and plantation...
PuraPharm Raises HK$20 Million via Convertible Bond Issue, Modestly Diluting Shareholders
Mar 23, 2026
PuraPharm Corporation Limited has completed the issuance of HK$20 million in convertible bonds under its general mandate, following the fulfilment of all conditions in the subscription agreement and the placement of the bonds with a single subscri...
PuraPharm Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 13, 2026
PuraPharm Corporation Limited has scheduled a board meeting for 25 March 2026 to review and approve the group’s audited annual results for the financial year ended 31 December 2025. At the same meeting, the board will also consider the publi...
PuraPharm Plans HK$20 Million Convertible Bond Issue Under General Mandate
Feb 26, 2026
PuraPharm Corporation Limited has entered into a conditional subscription agreement with an investor for the issue of HK$20 million in convertible bonds, which can be converted into shares at HK$0.49 each under its existing general mandate. The co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.